ArticleJAAD case reports2024

Two rashes, one patient: Enfortumab vedotin-induced interface dermatitis and pembrolizumab-induced psoriatic disease treated with ixekizumab.

Kyle Mueller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.